Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Poor Outcomes in Patients with Cirrhosis HP and COVID-19

    Authors: Shalimar; Anshuman Elhence; Manas Vaishnav; Ramesh Kumar; Piyush Pathak; Kapil Dev Soni; Richa Aggarwal; Manish Soneja; Pankaj Jorwal; Arvind Kumar; Puneet Khanna; Akhil Kant Singh; Ashutosh Biswas; Neeraj Nischal; Lalit Dhar; Aashish Choudhary; Krithika Rangarajan; Anant Mohan; Pragyan Acharya; Baibaswata Nayak; Deepak Gunjan; Anoop Saraya; Soumya Mahapatra; Govind Makharia; Anjan Trikha; Pramod Garg

    doi:10.21203/rs.3.rs-40220/v1 Date: 2020-07-06 Source: ResearchSquare

    Background and AimThere is a paucity of data on the clinical presentations and outcomes of Coronavirus disease MESHD 2019(COVID-19) in patients with underlying liver disease MESHD. We aimed to summarize the presentations and outcomes of COVID-19 positive patients and compare with historical controls.MethodsPatients with known chronic liver disease MESHD who presented with superimposed COVID- 19(n=28) between 22nd April and 22nd June 2020 were studied. Seventy-eight cirrhotic patients from historical controls were taken as comparison group.ResultsA total of 28 COVID patients- two without cirrhosis HP, one with compensated cirrhosis HP, sixteen with acute decompensation (AD), and nine with acute-on-chronic liver failure MESHD(ACLF) were included. The etiology of cirrhosis HP was alcohol(n=9), non-alcoholic fatty liver disease MESHD(n=2), viral(n=5), autoimmune hepatitis MESHD hepatitis HP(n=4), and cryptogenic cirrhosis HP(n=6). The clinical presentations included complications of cirrhosis HP in 12(46.2%), respiratory symptoms in 3(11.5%) and combined complications of cirrhosis HP and respiratory symptoms in 11(42.3%) patients. The median hospital stay was 8(7-12) days. The mortality rate in COVID-19 patients was 42.3%(11/26), as compared to 23.1%(18/78) in the historical controls(p=0.077). All COVID-19 patients with ACLF(9/9) died compared to 53.3%(16/30) in ACLF of historical controls(p=0.015). Mortality rate was higher in COVID patients with compensated cirrhosis HP and AD as compared to historical controls 2/17(11.8%) vs 2/48(4.2%), though not statistically significant (p=0.278). Requirement of mechanical ventilation independently predicted mortality (hazard ratio, 13.68). Both non-cirrhotic patients presented with respiratory symptoms and recovered uneventfully.ConclusionCOVID-19 is associated with poor outcomes in patients with cirrhosis HP, with worst survival rates in ACLF. Mechanical ventilation is associated with a poor outcome.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.